Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
Open Access
- 1 January 2008
- journal article
- clinical trial
- Published by Elsevier BV in Journal of Cardiovascular Magnetic Resonance
- Vol. 10 (1), 12
- https://doi.org/10.1186/1532-429x-10-12
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosisBlood, 2006
- Development of Thalassaemic Iron Overload Cardiomyopathy despite Low Liver Iron Levels and Meticulous Compliance to DesferrioxamineActa Haematologica, 2006
- Low Serum Ferritin Levels are Misleading for Detecting Cardiac Iron Overload and Increase the Risk of Cardiomyopathy in Thalassemia Patients. The Importance of Cardiac Iron Overload Monitoring Using Magnetic Resonance Imaging T2 and T2*Hemoglobin, 2006
- Reversal of heart failure in thalassemia major by combined chelation therapy: a case reportEuropean Journal of Haematology, 2004
- Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia majorBlood, 2004
- Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and DeathThe New England Journal of Medicine, 2004
- Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemiaJournal of Magnetic Resonance Imaging, 2003
- Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia RegisterThe Lancet, 2000
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorThe New England Journal of Medicine, 1994
- Current Treatment of Cooley's AnemiaAnnals of the New York Academy of Sciences, 1990